Cas:54986-53-7 3-benzyloxy-4-butylaniline manufacturer & supplier

We serve Chemical Name:3-benzyloxy-4-butylaniline CAS:54986-53-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-benzyloxy-4-butylaniline

Chemical Name:3-benzyloxy-4-butylaniline
CAS.NO:54986-53-7
Synonyms:3-benzyloxy-4-butylaniline
Molecular Formula:C17H21NO
Molecular Weight:255.35500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:401.6ºC at 760 mmHg
Density:1.054g/cm3
Index of Refraction:1.578
PSA:35.25000
Exact Mass:255.16200
LogP:4.77160

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3-benzyloxy-4-butylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-benzyloxy-4-butylaniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-benzyloxy-4-butylaniline Use and application,3-benzyloxy-4-butylaniline technical grade,usp/ep/jp grade.


Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances. 3-benzyloxy-4-butylaniline manufacturer To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. 3-benzyloxy-4-butylaniline supplier In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances. 3-benzyloxy-4-butylaniline vendor To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. 3-benzyloxy-4-butylaniline factory Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment.